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vertebral column. The Hough transform-based procedure with respect to the 
curve with three convexities allows identification of the spinal canal (blue line), 
while the spinal cord is detected by the Hough transform-based procedure with 
respect to the ellipse (green line). (b) Left to right: edge detection of a CT slice in 
the vertebral region; edge points inside the region bounded by the curve with 
three convexities; and the curve with three convexities (blue line) and the ellipse 
(green line) detected by applying the Hough transform-based procedure. ........... 11 
Figure 2: Panels A and C display two 3D reconstructions of SC FDG uptake, in a 
patient with upper or lower ALS onset, respectively. B panel reports the 
corresponding SUV values plotted from cervical slices (top) to lumbar ones 
(bottom). Tracer retention is higher in cervical segments in upper limb 
presentation, while the reverse gradient occurs in lower limb onset. Panel D 
displays average SUV values in the two SC districts: in patients with upper limb 
onset tracer uptake in the cervical SC is higher with respect to both the dorsal 
segment in the same patients and with respect to the same segment in the 
remaining subjects. This selective localization is confirmed by the ratio 
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3 About ALS 
Amyotrophic lateral sclerosis (ALS) is a group of rare neurological 
diseases that mainly involve the nerve cells (neurons) responsible for 
controlling voluntary muscle movement. The disease is progressive, and 
currently there is no cure for ALS and no effective treatment to halt, or 
reverse, the progression of the disease. 
ALS belongs to a wider group of disorders known as motor neuron 
diseases, which are caused by gradual degeneration and death of motor 
neurons. Motor neurons are nerve cells that extend from the brain to the 
spinal cord and to muscles throughout the body. These motor neurons 
initiate and provide vital communication links between the brain and the 
voluntary muscles. 
Messages from motor neurons in the brain (called upper motor 
neurons) are transmitted to motor neurons in the spinal cord and to 
motor nuclei of brain (called lower motor neurons) and from the spinal 
cord and motor nuclei of brain to a particular muscle or muscles. 
In ALS, both the upper motor neurons and the lower motor neurons 
degenerate or die, and stop sending messages to the muscles. Unable to 
function, the muscles gradually weaken, start to twitch (called 
fasciculations), and waste away (atrophy). Eventually, the brain loses its 
ability to initiate and control voluntary movements. 
Early symptoms of ALS usually include muscle weakness or stiffness. 
Gradually all muscles under voluntary control are affected, and 
individuals lose their strength and the ability to speak, eat, move, and 
even breathe. 
Most people with ALS die from respiratory failure, usually within 3 to 
5 years from when the symptoms first appear. However, about 10 
percent of people with ALS survive for 10 or more years. 
 
The onset of ALS can be so subtle that the symptoms are overlooked 
but gradually these symptoms develop into more obvious weakness or 
atrophy that may cause a physician to suspect ALS. Some of the early 
symptoms include: 
• fasciculations (muscle twitches) in the arm, leg, shoulder, or tongue 
• muscle cramps 
• tight and stiff muscles (spasticity) 
• muscle weakness affecting an arm, a leg, neck or diaphragm. 
• slurred and nasal speech 
• difficulty chewing or swallowing. 
For many individuals the first sign of ALS may appear in the hand or 
arm as they experience difficulty with simple tasks such as buttoning a 
shirt, writing, or turning a key in a lock.  In other cases, symptoms 
initially affect one of the legs, and people experience awkwardness 
when walking or running or they notice that they are tripping or 
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stumbling more often. 
When symptoms begin in the arms or legs, it is referred to as “limb 
onset” ALS.  Other individuals first notice speech or swallowing 
problems, termed “bulbar onset” ALS. 
 
No one test can provide a definitive diagnosis of ALS. ALS is 
primarily diagnosed based on detailed history of the symptoms and 
signs observed by a physician during physical examination along with a 
series of tests to rule out other mimicking diseases. However, the 
presence of upper and lower motor neuron symptoms strongly suggests 
the presence of the disease. 
Physicians will review an individual’s full medical history and 
conduct a neurologic examination at regular intervals to assess whether 
symptoms such as muscle weakness, atrophy of muscles, and spasticity 
are getting progressively worse. 
ALS symptoms in the early stages of the disease can be similar to 
those of a wide variety of other, more treatable diseases or disorders.   
 
The cause of ALS is not known, and scientists do not yet know why 
ALS strikes some people and not others. However, evidence from 
scientific studies suggests that both genetics and environment play a 
role in the development of ALS. 
 
No cure has yet been found for ALS. However, there are treatments 
available that can help control symptoms, prevent unnecessary 





As mentioned, ALS is a neurodegenerative disorder, characterized 
by a degeneration of upper and lower motor neurons leading to a 
progressive muscular paralysis. Although median survival most 
often  averages 3–5 years, the large variability of its course (Calvo 
et al., 2017 [7]) raises an urgent need to develop biomarkers able 
to characterize the mechanisms underlying disease progression and 
to improve the diagnostic yield of clinical and neuro-physiological 
evaluation. 
Most studies in this setting focused on cortical response to ALS. 
Among these approaches, brain PET studies with 18F-
fluorodeoxyglucose (FDG) already reported a significant reduction 
in glucose metabolism (Pagani et al., 2014 [30]) in motor and 
premotor cortex (Kiernan et al., 1994 [15]; Abrahams et al., 1996 
[1], 2005 [2]). By contrast, involvement of the spinal cord has 
been characterized in relatively lower detail, mostly because of the 
anatomical features of this structure that limit the standardization of 
its evaluation. Consequently, a large uncertainty still exists about 
the mechanisms underlying ALS-induced damage in the spinal cord 
and its relationship with cortical impairment. We recently 
reported the potential of the Hough transform in delineating spinal 
cord structure and metabolic activity in a population of ALS 
patients subjected to FDG PET/CT (Marini et al., 2016 [23]). 
Specifically, this classical pattern recognition approach for the 
automatic identification  of straight lines in the image has been 
recently extended to the recognition of more complex shapes. This 
computational 3D approach enabled the extraction of spinal cord 
metabolic information from whole body images and permitted us 
to document increased glucose consumption, possibly representing 
a potential and independent prognostic marker (Marini et al., 2016 
[23]). 
In the present study, we simultaneously analysed brain and 
spinal cord FDG uptake in a series of prospectively recruited 






5 Materials and methods 
5.1 Patients with amyotrophic lateral sclerosis 
The study included 44 prospectively recruited patients with 
definite, probable or probable laboratory-supported ALS diagnosis 
according to  the  revised  El-Escorial  criteria  (Brooks et  al.,  
2000 [6]).  None  of  them  had  any  history  of  other 
neurological disorders, cerebrovascular disease, diabetes mellitus or 
systemic inflammatory disease. All subjects provided signed 
informed consent to enter the study that was approved by the 
Ethics Committees of IRCCS Ospedale Policlinico San Martino in 
Genoa, and of AUO Città della Salute e della Scienza in Turin, 
Italy. 
 
5.2 Control subjects 
Brain PET from patients with ALS were compared with the 
corresponding data of 44 healthy volunteers who gave their informed 
consent. As described by Morbelli et al. (2017 [26]), their healthy 
condition was carefully checked by means of clinical and 
neuropsychological examination, brain MRI and by the same 
exclusion criteria as used for ALS patients. A case–control criterion 
was adopted to reproduce the same age range, gender distribution 
and educational level of ALS patients. 
For ethical considerations, PET/CT scan was not extended to the 
body of these normal volunteers. Accordingly, PET spinal cord data 
were compared with the corresponding findings of 44 control 
subjects without any history of neurodegenerative disease, randomly 
selected from a previously published normalcy database (Sambuceti 
et al., 2012 [33]), again according to a case–control criterion. 
 
5.3 PET/CT imaging 
All PET/CT scans were acquired according to current guidelines 
(Varrone et al., 2009 [35]) 
All subjects were studied in the early morning after ≥6 h fasting. 
Serum glucose was assessed, and an antecubital vein was cannulated. 
According to current guidelines (Hoffman et al., 1992 [13]), patients 
were invited to lye for 20 min in a silent and darkened room, with eyes 
closed and ears unplugged. A bolus of FDG (4.8-5.2 MBq/kg body 
weight) was then injected 45-60 minutes before 3D-scan using an 
integrated PET/CT scanner (Hirez 16, Siemens Medical Solutions or 
Discovery GE Healthcare, depending on the centre). In all cases, the 15 
minutes cerebral acquisition was followed by whole body imaging in 
arms down position.  
In both centers, PET data were reconstructed into a 128 × 128 matrix 
using a 3D iterative reconstruction algorithm (ordered-subsets 
9 
 
expectation maximization, three iterative steps, eight subsets). Raw 
images were scatter-corrected and processed using a 3D Gaussian filter, 
while CT was used for attenuation correction.  
Image quality control documented a spatial resolution of 4.0 mm full-
width at half-maximum for both scanners. According to standard 
procedures of both labs, the two imaging systems were cross-calibrated 
using a cylinder of 20 cm diameter and 20 cm length filled with a 
solution containing 100 MBq of 18F-FDG that was counted for 1 h to 
minimize the statistical noise, and images were reconstructed with the 
same algorithm used for the clinical protocol. 
 
5.4 Spinal cord analysis 
The entire CT dataset was co-registered with the 3D PET images 
using commercially available software interfaces. 
Image analysis was performed by means of a pattern recognition 
algorithm based on an extension of the Hough transform to algebraic 
curve. This approach uses an operator-independent fully 
deterministic algorithm to identify the spinal canal and to  extract  
spinal cord FDG uptake expressed as standardized uptake value 
(SUV) 
The computational method has been previously described by Ricca 
et al. (2016 [31]). 
It was first observed that spinal cord profile is reliably 
approximated by an ellipse. Let 𝑝𝑝 = (𝑥𝑥𝑝𝑝,𝑦𝑦𝑝𝑝) be a point in the image 










Then, the Hough transform of p with respect to the family of curves 
ℱ = �𝒞𝒞𝑎𝑎,𝑏𝑏� , is the curve Γ𝑝𝑝(ℱ) of equation 
 
Γ𝑝𝑝(ℱ): 𝐵𝐵2𝑥𝑥𝑝𝑝2 + 𝐴𝐴2𝑦𝑦𝑝𝑝2 = 𝐴𝐴2𝐵𝐵2 
 
in the parameter space 〈𝐴𝐴,𝐵𝐵〉 where the two real, positive, and 
independent parameters 𝑎𝑎, 𝑏𝑏 vary. The Hough transform method 
relies on the mathematical fact that when 𝑝𝑝  varies on 𝒞𝒞𝑎𝑎,𝑏𝑏 then all 
curves Γ𝑝𝑝(ℱ) intersect in exactly one point in the parameter space. 
From a computational viewpoint this fact naturally inspires a pattern 
recognition method according to which the parameter space is 
discretized in cells, an accumulator function is defined on it, and the 
ellipse in the image space is identified by the parameters providing 
the maximum of such function. This method can be extended to the 
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recognition of a vast class of algebraic curves in the image space. 
Moreover, Beltrametti et al. (2013 [5]) showed that the method is 
robust with respect to both image noise and spatial inaccuracy in the 
image. Finally, the Hough transform technique shows a better 
sensitivity with respect to standard gradient-based methods, since it 
behaves reliably even in the case of low contrast. 
We applied this scheme to the recognition of both the spinal canal 
and the spinal cord districts in whole-body CT images of control 
subjects and ALS patients. Specifically, the family of curves with 
three convexities, represented by the equation 
 




was particularly appropriate for the optimal detection of the spinal 
canal (Figure 1). 
By contrast, the four-parameter family of ellipses expressed in the 
form 
 
𝐸𝐸𝑎𝑎,𝑏𝑏,𝑐𝑐,𝑑𝑑:𝑏𝑏2(𝑥𝑥 − 𝑐𝑐)2 + 𝑎𝑎2(𝑦𝑦 − 𝑑𝑑)2 − 𝑎𝑎2𝑏𝑏2 = 0 
 
was the best candidate for identifying the spinal cord district. 
For each CT slice, the two curves identifying the spinal canal and 
SC were used to create two sets of binary masks with one zero 
outside and one inside each curve, respectively. These masks were 
multiplied against the co-registered PET slice in order to digitally 
extract the metabolic information represented as standardized uptake 
value (SUV) of local FDG radioactivity 
The different spinal canal and spinal cord districts were defined 
anatomically considering the cervical segment as the region between 
the skull base and the plane adjacent to the caudal face of the C7 
vertebral body. The dorsal segment was defined as the district 
between this plane and the one adjacent to the caudal face of D12. 
The sacral and lumbar canal districts were a priori excluded since 





Figure 1: (a) Detection of spinal canal and spinal cord at different heights of the vertebral column. 
The Hough transform-based procedure with respect to the curve with three convexities allows 
identification of the spinal canal (blue line), while the spinal cord is detected by the Hough 
transform-based procedure with respect to the ellipse (green line). (b) Left to right: edge detection 
of a CT slice in the vertebral region; edge points inside the region bounded by the curve with three 
convexities; and the curve with three convexities (blue line) and the ellipse (green line) detected 
by applying the Hough transform-based procedure. 
 
5.5 Brain PET analysis 
Statistical Parametric Mapping (SPM) analysis was performed as 
previously described (Morbelli et al., 2017 [26]). 
Original DICOM images were converted to NifTI-1 format using 
SPM8 DICOM Import (Varrone et al., 2009 [35]). PET images were 
normalized to a customized previously published template (Della 
Rosa et al., 2014 [10]) and smoothed with 8-mm full width at half 
maximum Gaussian Kernel. Subsequently, tracer distribution was 
scaled for whole brain radioactivity concentration to identify areas of 
relative hypo- or hypermetabolism in ALS group by means of a two-
sample t test. The same algorithm was used to analyze FDG 
distribution within ALS group according to either disease 
presentation (bulbar or spinal) and side involvement at diagnosis. 
Finally, multiple regression analysis was performed to identify areas 
whose metabolism was directly o inversely correlated with SC SUV. 
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This analysis was performed without any a priori definition, 
considering SC SUV as covariate. Age, gender and center of 
belonging were included as nuisance in all SPM analyses with 
significance threshold set at p<0.05, False-Discovery-Rate (FDR)-
corrected both at peak and at cluster level. Only significant clusters 
containing at least 100 voxels were taken into consideration. 
BrainMap GingerALE 2.3 (Eickhoff SB, Laird AR.) was used to 
convert coordinates of significant clusters in Montreal Neurological 
Institute space into Talairach coordinates. Brodmann areas (BAs) 
were then identified at a range of 0 to 3 mm from the corrected 
Talairach coordinates of the SPM output isocenters, after importing 
the corrected coordinates by means of Talairach client 
(http://www.talairach.org/index.html). 
To compare ALS effects on global consumption of brain and spinal 
cord, SPM analysis of FDG uptake distribution was complemented  
with  the  evaluation of absolute tracer retention. Accordingly, the 
preprocessed NifTI-1 PET images were converted in whole-brain 
SUV parametric maps dividing the product between radiotracer 
concentration (kBq/ml) and body weight (in kg) by the injected FDG 
dose (in MBq) (Cistaro et al., 2012 [8]; Ku¨ntzelmann et al., 2013 
[17]; Annen et al., 2016 [3]). 
Thereafter, we automatically identify volumes of interest 
corresponding to 41 Brodmann areas (BAs) in both hemispheres. 
Our Volumes Of Interest (VOIs) masks were created using WFU 
PickAtlas (Lancaster et al., 1997 [18], 2000 [19]) and we used 
NiftyReg (TIG, Translational Imaging Group) to register the Atlas’s 
reference image on each patient’s PET; using these transformations 
we were able to register each mask on the corresponding PET, in 
order to extract PET signal (SUV) from each VOI. 
All data are reported as mean ± standard deviation (SD). Unpaired 
or paired t-tests were used, as appropriate. P-values < 0.05 were 
considered significant. Analyses were performed using SPSS 





6.1 Clinical characteristics of patient population 
As reported in Table 1, age, sex, and ideal body weight were 
similar in control and ALS subjects. ALS Functional Rating Scale 
Revised (ALSFRS-R) score, updated at imaging date, was 39 ± 4  
(range 28–45). Mean time elapsed from clinical disease onset 
and PET/CT scanning was 20 ± 15 months (range 8–81 months, 
median 14 months) while mean interval between ALS diagnosis 
and imaging was 10 ± 9 months. 
 
Table 1: Demographic of patients population 
Number 44 
Age (years) 64±10 
Men 25 
Women 19 
Spinal onset 35 (80%) 
Bulbar onset 9 (20%) 
Right sided  16/35  
Left sided  14/35 
Bilateral   5/35 
Upper limb onset  12 / 35 
Lower limb onset  21 / 35 
Combined limbs onset  2 / 35  
Time elapsed from ALS diagnosis 
and PET/CT imaging (months) 
10±9 
ALS functional rating scale 39±5 
 
 
6.2 Spinal cord metabolism 
FDG uptake was significantly higher in the whole spinal cord 
of ALS patients with respect to controls (0.81 ± 0.4 versus 0.67 ± 
0.2, P = 0.05). This difference was more pronounced in cervical     
segments (1.08 ± 0.2 versus 0.82 ± 0.2, P < 0.01) and relatively less 
evident in dorsal metameres (0.69 ± 0.2 versus 0.57 ± 0.2, P < 
0.05). Effect of ALS on spinal cord metabolism was independent 
from demographic and clinical variables as  well as  from time 
elapsed from diagnosis to imaging. Likewise, spinal cord 
metabolic activation was similar in spinal or bulbar onset ALS. 
Yet, the regional agreement between increased FDG uptake and 
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clinical motor impairment could be documented in the 33/35 spinal 
patients in whom predominantly upper (n = 12) or lower (n = 21) 
limb involvement was well defined at diagnosis (Figure 2). 
Upper limb onset was associated with a more pronounced 
metabolic activation in the cervical segment (Figure 2). The 
selectivity of this metabolic response was confirmed by the ratio 
between cervical and dorso-lumbar spinal cord tracer retention that 
was significantly  higher in  patients with  upper limb. 
 
 
Figure 2: Panels A and C display two 3D reconstructions of SC FDG uptake, in a patient with upper 
or lower ALS onset, respectively. B panel reports the corresponding SUV values plotted from 
cervical slices (top) to lumbar ones (bottom). Tracer retention is higher in cervical segments in 
upper limb presentation, while the reverse gradient occurs in lower limb onset. Panel D displays 
average SUV values in the two SC districts: in patients with upper limb onset tracer uptake in the 
cervical SC is higher with respect to both the dorsal segment in the same patients and with respect 
to the same segment in the remaining subjects. This selective localization is confirmed by the ratio 





6.3 SPM analysis of  amyotrophic lateral sclerosis effect on 
brain FDG distribution 
SPM-based group analysis highlighted a wide hypometabolic 
cluster involving frontal dorso-lateral cortex bilaterally as well as 
the precentral and temporal cortex in the left hemisphere (Figure 
3A and Table 2). Conversely, hypermetabolic cluster was markedly 
smaller and mainly involved the midbrain (Figure 3B and Table 2). 
This metabolic pattern was reproduced in spinal as well as in 
bulbar onset patients. Bulbar onset was instead associated with a 
more severe metabolic impairment in bilateral  precentral gyri (BA 
6) and in left putamen (Figure 4 and Table 3). 
Among the 35 patients with spinal ALS, right onset was 
associated with a more severe metabolic impairment in the left 
premotor cortex (BA 6) and in the left temporal cortex (BA 39) as 
well as in the right postcentral gyrus (BA 3) (Figure 5 and Table 
4). By contrast, no appreciable difference in brain metabolism was 
identified between ALS patients classified according to upper or 
lower limb clinical onset. 
Mean SUV of cervical spinal cord was significantly and 
inversely correlated with hypometabolism in the pre- and para-
central gyri bilaterally but particularly in the left hemisphere 
(Figure 3C and Table 2). Similarly, dorsal spinal cord mean SUV 
predicted a relative hypometabolism in the temporo-lateral and 
frontal dorso-lateral cortex in the left hemisphere (Figure 3D and 
Table 2). Finally, neither cervical nor dorsal spinal cord metabolism 





Figure 3: SPM analysis. 3D rendering showing regions in which FDG uptake was significantly lower 
(A) or higher (B) in ALS patients with respect to controls. (C and D) Results of the multiple 
regression analysis between brain and cervical or dorsal spinal cord metabolism, respectively. 
Threshold P<0.05, corrected for multiple comparisons with the FDR at the voxel level were set in 




Table 2: SPM analysis 
 Cluster level  Peak level 
Cluster Corrected Cortical  Maximu
 
Talairach Coordinates Cortical BA 
Extent P-value region  Z-score x, y, z region  
 
Cortical regions of relative hypometabolism 
 
1357 0.0001 L-limbic  5.48 -33 -9 -34 Uncus 20 
  L-limbic  5.35 -36 -18 -26 Uncus 20 
  L-temporal  4.78 -45 -22 -21 Fusiform gyrus 20 
1619 0.0001 L-frontal  5.06 -49 1 45 Middle frontal gyrus 6 
  L-frontal  4.97 -32 15 51 Superior frontal  
8 
  R-frontal  4.58 15 30 49 Superior frontal  
8 
 
Cortical regions of relative hypermetabolism 
 
384 0.01 R-frontal  5.19 11 -19 -13 Superior frontal 
 
8 
  R-sublobar  4.74 23 -8 -8 Amygdala  
  R-sublobar  3.83 13 -2 0 Lentiform nucleus  
  R-sublobar  3.50 36 -9 16 Insula 13 
379 0.01 R-midbrain  4.69 7 -18 -19   
 
Correlation between cervical spinal cord and brain metabolism 
 
349 0.01 L-frontal  4.13 -5 -40 57 Paracentral lobule 5 
  R-frontal  4.11 15 -24 69 Precentral gyrus 4 
  L-frontal  3.62 -5 -30 56 Paracentral lobule 6 
 
Correlation between dorsal spinal cord and brain metabolism 
 
409 0.01 R-sublobar  4.75 42 -7 16 Insula 13 
  R-sublobar  3.55 41 4 12 Insula 13 
  R-sublobar  3.39 34 -14 15 Claustrum  
347 0.01 L-frontal  4.46 -13 23 49 Superior frontal  
6 
  L-limbic  3.79 -7 17 37 Cingulate gyrus 32 
  L-limbic  3.48 -5 0 42 Cingulate gyrus 24 
590 0.01 L-sublobar  4.07 -34 -9 15 Insula 13 
  L-sublobar  3.49 -36 -2 23 Insula 13 
  L-frontal  3.30 -41 6 36 Precentral gyrus 9 
436 0.01 L-frontal  3.55 -49 35 18 Middle frontal gyrus  
  L-frontal  3.16 -25 34 21 Medial frontal gyrus 9 




Figure 4: Topographic localization of hypometabolic clusters in bulbar versus spinal ALS. SPM 
analysis was performed with threshold set at p<0.05, FWE corrected. Cluster, extension and 
localization is also described in the Table 3.  
 
Table 3: SPM analysis in bulbar versus spinal ALS 






region Maximum Z score 
Talairach Coordinates 
x, y, z 
Cortical 
Region BA 
547 0.0001 L-Sub Lobar 5.75 -29 -4 -1 Putamen  
  L-Sub Lobar 5.57 -31 -12 0 Putamen  
  L-Frontal 5.25 -22 6 -11 Subcallosal 
Gyrus 
34 
  L-Frontal 5.66 -37 -13 29 Precentral 
Gyrus 
6 
131 0.0001 R-Frontal 5.53 50 -9 31 Precentral 
Gyrus 
6 







Figure 5: Comparison between right and left ALS clinical onset. Cluster were regarded as 
significant if they survived at p<0.005, no FWE corrected. SPM analysis was performed with 
threshold set at p<0.005 no FWE corrected. Panel A shows the topographic representation of 
clusters in which FDG uptake was significantly lower in right than in left clinical onset ALS patients. 
Panel B represents the clusters in which FDG uptake was significantly lower in left than in right 





Table 4: SPM analysis in left and right clinical onset 












Left < Right 
 








225 0.038 L-Limbic 3.70 -19 -57 6 Posterior 
Cingulate 
30 
204 0.047 R-Frontal 3.69 32 -25 65 Precentral 
Gyrus 
4 
  R-Parietal 3.15 45 -25 60 Postcentral 
Gyrus 
3 








145 0.087 L-Frontal 3.37 -54 -7   34 Precentral 
Gyrus 
6 
  L-Frontal 2.85 -43 -11 31 Precentral 
Gyrus 
6 
         
Right < Left 
 




6.4 Volumes of interest analysis 
FDG uptake, estimated by average SUV of automatically identified 
volumes of interest, was significantly lower  in ALS patients with 
respect to controls in virtually all analysed BAs (Figure 6). As a 
consequence, this same observation also applied when the average 
SUV of the whole cortical volume was considered (4.93 ± 1.40 
versus 5.95 ± 1.65, respectively, P < 0.01). Similarly, ALS was 
associated with lower SUV in thalamus (5.31 ± 1.76 versus 6.4 ± 
1.7, respectively, P < 0.01), basal ganglia (6.17 ± 1.75 versus 7.2 ± 
2.0, respectively, P < 0.01)  and cerebellum  (3.1 ± 1.98  versus 5.6 
± 1.5, respectively, P < 0.01). 
 
 
Figure 6: Volumes of interest analysis. BA SUV values in ALS (filled bars) and control subjects (open 
bars) according to cortical lobes. The y-axes represent BA SUV values. Yellow = frontal lobe; green 






The main finding of the present study is the divergent metabolic 
response to ALS in brain and spinal cord. Brain displays a 
generalized reduction in glucose consumption   particularly   
evident   in   motor   and   premotor cortex. By contrast, spinal cord 
displays a moderate increase in FDG uptake that can be more 
easily detected in its cervical segment. The interplay between the 
two opposite metabolic patterns, documented by this transversal 
and simultaneous picture, indicates a divergent nature or a 
divergent time-course of the mechanisms underlying ALS-related 
damage to upper and lower motor neurons. 
In agreement with our previous observation (Marini et al., 2016 
[23]), the analysis of spinal cord metabolic pattern showed a 
significant increase in FDG uptake in the spinal cord of ALS 
patients. The reproducibility of this finding and its occurrence in a 
cohort of prospectively and independently recruited ALS subjects 
confirm that ‘metabolic spinal cord activation’ might occur in a 
high number of ALS patients and might thus track 
pathophysiological mechanisms potentially contributing to disease 
progression. This concept is corroborated by the observation that, 
among spinal onset ALS patients, upper limb presentation was 
associated with a more pronounced metabolic activation of cervical 
spinal cord. This finding thus suggests that spinal cord metabolic 
activation might track some process related to motor impairment on 
a regional basis. Actually, the opposite pattern was not observed in 
patients with lower limb involvement most likely because of the 
limited spatial resolution hampering the evaluation of caudal spinal 
cord because of contaminations related to both partial volume effect 
and uncertainty in the definition of caudal spinal cord border. 
On the other hand, SPM analysis of brain FDG distribution 
confirmed previous studies in larger numbers of patients reporting 
small areas of relative hypermetabolism virtually limited to the 
midbrain and large hypometabolic clusters in the frontal dorso-
lateral cortex (Cistaro et al., 2012 [8]; Pagani et al., 2014 [30]) 
with the uncus involved only in our series. 
Bulbar phenotype was characterized by a more pronounced 
metabolic impairment in bilateral pre-central gyri and in left 
putamen. This finding agrees with data by Kim et al. [16] who 
reported that the putamen was among the most atrophied brain 
regions in cognitively impaired ALS patients. On the other hand, the 
finding of a relatively reduced bilateral frontal metabolism supports 
the growing evidence of cognitive and extramotor changes in bulbar 
pathology and seems to confirm the divergent neuropsychological 
and functional patterns in bulbar and spinal onset ALS. 
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Right onset ALS was associated with a more severe metabolic 
impairment in the left hemisphere at SPM analysis. However, this 
finding has to be cautiously interpreted due to the possible 
occurrence of several biases related to the limited sample size and 
the variable side with most prominent symptoms at time of scan. 
Accordingly, the simultaneous coupling of both evaluations 
provided a new and, under many points of view, unexpected glance 
at available data about ALS metabolic effect on the CNS (central 
nervous system). 
Currently, SPM is one of the most widely used standards to 
evaluate brain FDG images. In conventional ‘static’ PET studies, 
this procedure analyses the original reconstructed data reporting 
radioactivity concentration (in kBq/ml) in each voxel. These source 
images are thus scaled to an intracranial reference region to 
identify areas of relative activation (hypermetabolism) or stilling 
(hypometabolism). However, scaling procedure intrinsically prevents 
the capability to identify generalized reductions in brain glucose 
consumption. Indeed, several authors argued about the interpretation 
of voxelwise-highlighted hypermetabolic clusters that might reflect a 
true metabolic activation as well a relatively less severe metabolic 
deceleration in neurodegenerative disorders (Ku¨ntzelmann et al., 
2013 [17]). 
To overcome this limitation, and to replicate the analysis criteria 
adopted for spinal cord evaluation, we processed the original data 
of tracer concentration to calculate average SUV in each 
automatically detected volume of interest. Obviously, this 
procedure does not account for both FDG persistence in the 
circulating blood and competition by serum glucose level. 
Nevertheless, its capability to abolish the interference of the main 
methodological determinants of tracer uptake administered dose and 
body weight permitted us to detect a generalized  reduction  of  FDG 
uptake in studied ALS patients. 
This finding confirms previous dynamic PET studies that reported a 
generalized and progressive reduction of glucose consumption in 
ALS brain partially related to disease duration (Dalakas et al., 1987 
[9]), degree of cognitive decline (Ludolph et al., 1992 [22]) or 
severity of upper motor neuron involvement (Hoffman et al., 1992 
[13]). Similarly, localization of metabolic impairment, provided by 
voxelwise analysis, closely agrees with the thinning of the primary 
motor cortex previously documented by MRI in ALS patients 
(Verstraete et al., 2010 [36]) and also with recent (Eisen et al., 2017 
[11]) and older neuropathological studies reporting abnormalities not 
only in the Betz area (Lawyer et al., 1953 [20]) but also in the 
adjacent gyri and in the deeper parts of the  brain (Smith et al., 1960 
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[34]). Unfortunately, the lack of coregistered PET and MRI images 
prevents the possibility to define whether the reduced tracer uptake in 
hypometabolic areas reflects a reduced density of cells with an intact 
metabolism, a reduced metabolic rate of glucose consumption by 
normal populations of synapses or both mechanisms. Nevertheless, 
the same analytical approach documented that the metabolic 
activation of spinal cord faced a global impairment in glucose 
consumption involving the vast majority of encephalic structures. 
The mechanisms underlying this opposite response cannot be 
identified by the present data. Nevertheless, post-mortem studies 
document the activation of microglia (Beers et al., 2006 [4]), 
oligodendrocytes (Lee et al., 2012 [21]) and astrocytes (Nagai et al., 
2007 [28]) in tissues harvested from motor cortex  and  spinal  cord  
of  both  ALS  patients  and experimental models of ALS. In 
particular, astrocytic activation nicely fits with the notion that these 
cells account for most of the FDG accumulation in the brain 
(Zimmer et al., 2017 [37]). Defining these mechanisms is obviously 
far beyond the scope of this clinical and observational study. 
Nevertheless, the divergent pattern of FDG uptake in the spinal cord 
and brain indicates that the metabolic response of these two districts 
follows different pathways or different time sequences. Accordingly, 
monitoring the temporal evolution of damage in the first and in the 
second motor neuron might represent an important clue to improve 
our understanding of ALS pathophysiology. Obviously, a direct 
estimation of brain glucose consumption would have provided a 
more detailed description of metabolic pattern in both brain and 
spinal cord (Hustinx et al., 1999 [14]). Ethical concerns prevented 
the possibility to perform a complex series of acquisitions with 
dynamic sequence followed by brain and whole-body scans. 
Nevertheless, the decreased FDG uptake in the brain, together with 
the opposite response of spinal cord SUV, strongly support the 
concept  that  hypermetabolic  brain clusters identified by SPM 
analysis probably reflect areas of relatively preserved glucose 
consumption rather than the consequence of neuronal activation 
(Pagani et al., 2014 [30]). 
As a main limitation of our study, brain and spinal cord metabolic 
patterns of ALS patients were compared with normalcy databases 
harvested from different populations. In brain-image donors, this 
limitation was justified by the ethical concern in extending CT scan 
to the whole body of normal volunteers. For normal spinal cord 
evaluation, the ethical concern was related to the need to avoid 
modifications to the standard protocol of oncologic imaging that does 
not include the pre-scan procedure needed for cerebral PET/CT. As a 
further limitation, the limited patient sample and the relatively wide 
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inclusion criteria did not permit us to verify any possible correlation 
between degree/site of spinal cord metabolic activation and force 
generated by the related muscular districts. A similar consideration 
applies to the side coherence between brain metabolism and motor 
involvement. Actually, when compared with left onset, right onset 
ALS was associated with a more severe   metabolic   impairment   in   
the   left   hemisphere. 
However, this finding must be interpreted cautiously because of the 
possible occurrence of several biases related to the limited sample 
size and the variable side with most prominent symptoms at time of 
scan. 
In conclusion, the present transversal and observational study 
documents a divergent metabolic response to ALS by spinal cord and 
brain. This evidence indicates that whatever mechanism affects 
glucose consumption of the CNS in ALS, its nature or its time course 
profoundly differ in upper and lower motor neurons. This divergent 
behaviour indicates that complementing brain imaging with the 
extraction of spinal cord information might improve the informative 
potential of PET studies with tracers selectively interrogating specific 
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17. Küntzelmann A, Guenther T, Haberkorn U, Essig M, Giesel 
F, Henze R, et al.  Impaired cerebral glucose metabolism in 
prodromal Alzheimer’s disease differs by regional intensity 
normalization. Neurosci Lett 2013; 534: 12–7. 
18. Lancaster, J.L., Summerln, J.L., Rainey, L., Freitas, C.S., Fox, 
P.T., 1997. he Talairach Daemon, a database server for Talairach 
Atlas Labels. NeuroImage 5, S633. 
19. Lancaster, J.L., Woldorff, M.G., Parsons, L.M., Liotti, M., 
Freitas, C.S., Rainey, L., Kochunov, P.V., Nickerson, D., 
Mikiten, S.A., Fox, P.T., 2000. Automated Talairach atlas labels 
for functional brain mapping. Hum. Brain Mapp. 10, 120–131 
20. Lawyer T, Netsky MG. Amyotrophic lateral sclerosis. A 
clinicoanatomic study of fifty-three cases. Arch Neurol 
Psychiatry 1953; 69: 171–92. 
21. Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, 
Hoffman PN, et al. Oligodendroglia metabolically support 
axons and contribute to neurodegeneration. Nature 2012; 
487: 443–8. 
22. Ludolph AC, Langen KJ, Regard M, Herzog H, Kemper B, 
Kuwert T, et al. Frontal lobe function in amyotrophic lateral 
sclerosis: a neuropsychologic and positron emission 
tomography study.  Acta Neurol Scand 1992; 85: 81–9. 
23. Marini C, Cistaro A, Campi C, Calvo A, Caponnetto C, 
Nobili FM, et al. A PET/CT approach to spinal cord 
metabolism in amyotrophic lateral sclerosis. Eur J Nucl Med 








24. Marini C, Morbelli S, Cistaro A, Campi C, Caponnetto C, 
Bauckneht M, Bellini A, Buschiazzo A, Calamia I, Beltrametti 
MC, Margotti S, Fania P, Poggi I, Cabona C, Capitanio S, Piva 
R, Calvo A, Moglia C, Canosa A, Massone AM, Nobili F, 
Mancardi G, Chio` A, Piana M, Sambuceti G. Interplay between 
spinal cord and cerebral cortex metabolism in amyotrophic 
lateral sclerosis. BRAIN 2018: 141; 2272–2279 
25. Massone AM, Perasso A, Campi C, Beltrametti MC. Profile 
detection in medical and astronomical images by means of 
the Hough transform of special classes of curves. J Math 
Imaging Vis 2015; 51: 296–310. 
26. Morbelli S, Bauckneht M, Arnaldi D, Picco A, Pardini M, 
Brugnolo A, et al. 18F-FDG PET diagnostic and prognostic 
patterns do not overlap in Alzheimer’s disease (AD) patients 
at the mild cognitive impairment (MCI) stage. Eur J Nucl 
Med Mol Imaging 2017; 44: 2073–83. 
27. Morbelli S, Rodriguez G, Mignone A, Altrinetti V, Brugnolo 
A, Piccardo A, et al. The need of appropriate brain SPECT 
templates for SPM comparisons. Q J Nucl Med Mol Imaging. 
2008;52:89-98. 
28. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, 
Wichterle H, et al. Astrocytes expressing ALS-linked 
mutated SOD1 release factors selectively toxic to motor 
neurons. Nat Neurosci 2007; 10: 615–22. 
29. NIH, National Institute of Neurological Disorders and Strokes 
https://www.ninds.nih.gov/ 
30. Pagani M, Chio` A, Valentini MC, O¨ berg J, Nobili F, Calvo 
A, et al. Functional pattern of brain FDG-PET in amyotrophic 
lateral sclerosis. Neurology 2014; 83: 1067–74. 
31. Ricca G, Beltrametti M C, Massone A M. Detecting curves of 
symmetry in image via Hough transform. Math. Comp. Sci. 
2016; 10(1): 179-205 
32. Robinson JD, Lupkiewicz SM, Palenik L, Lopez LM, Ariet 
M. Determination of ideal body weight for drug dosage 
calculations. Am J Hosp Pharm. 1983;40:1016–9 
33. Sambuceti G, Brignone M, Marini C, Massollo M, Fiz F, 
Morbelli S, et al. Estimating the whole bone-marrow asset in 
humans by a computational approach to integrated PET/CT 
imaging. Eur J Nucl Med Mol Imaging 2012; 39: 1326–38. 
34. Smith MC.  Nerve fiber degeneration in the brain in 
amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatr 





35. Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili 
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